INTRODUCTION
The development of the Xpert ® Mycobacterium tuberculosis/ rifampicin (MTB/RIF) assay for the GeneXpert platform was completed in 2009 and is considered an important breakthrough in the fight against tuberculosis (TB). For the first time, a molecular test is simple and robust enough to be introduced and used outside conventional laboratory settings. MTB is detected by the five overlapping molecular probes (Probes A-E) that collectively are complementary to the entire 81 bp rpoB core region. [1] [2] [3] [4] MTB is identified when at least two of the five probes give positive signals with a cycle threshold (Ct) of ≤38 cycles and that difference is by no more than a prespecified number of cycles. The Bacillus globigii internal control is positive when the single B. globigii-specific probe produces a Ct of ≤38 cycles. The standard user interface indicates the presence or absence of MTB and the presence or absence of RIF resistance and a semiquantitative estimate of the concentration of Bacilli as defined by the Ct range (high, 28). Assays that are negative for MTB and for the B. globigii internal control are reported as invalid assays. When performed on unprocessed
General Perspective
The development and rollout of the Xpert ® Mycobacterium tuberculosis/rifampicin assay for the GeneXpert platform is considered an important breakthrough in the fight against tuberculosis. Xpert though robust is known to have issues that occur with very low load of tuberculosis detection, wherein it is recommended to confirm resistance if resistance is not suspected using another genotypic test.
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10.4103/lungindia.lungindia_463_18 not detected and the remaining 4819 were MTB detected. Among these 4819 MTB-positive samples, 166 samples were detected with very low load of MTB. Table 1 depicts the number of samples and the load that were diagnosed by Xpert.
RESULTS
A total of 166 samples were found to be Xpert very low for the detection of MTB, of these 40 were Xpert RIF resistant and 96 were Xpert RIF susceptible. Among the RIF susceptible, mycobacterial growth indicator tube (MGIT) drug susceptibility testing (DST) RIF was susceptible in 92 and resistant in 4. These four samples have been sent for the whole-genome sequencing, and the results are awaited.
Among the Xpert RIF resistant, MGIT DST was resistant in 27 samples and susceptible in 13. Pyrosequencing (PSQ) showed mutation in 27 samples that were DST RIF resistant. Thirteen samples were susceptible to RIF by MGIT DST; among these, three samples showed mutation with PSQ. These mutations fall under the disputed category, for which the gold standard is challenged [ Figure 1 ]. There were ten samples that were susceptible by both PSQ and MGIT DST, and Xpert was resistant due to Ct difference.
Analysis of 40 samples where Xpert MTB very low with RIF resistance was done. The PSQ performed for all these 40 samples was compared with the results of MGIT RIF DST [ Table 2 ]. There were ten samples that showed a discrepancy between Xpert results and MGIT DST. The PSQ results of these samples showed no mutation in the RIF resistance determining the region. When the Xpert MTB/RIF Ct was evaluated, 8/10 samples showed a Ct difference of >3.5, whereas two samples showed probe Ct value to be zero. It was observed that when any of the Ct values were absolute zero, a mutation was observed in PSQ and the corresponding DST was also resistant to RIF. This was observed in 30/40 samples. There was a single sample that showed Ct difference among the probes, but it showed a mutation in PSQ and was found to be RIF resistant with MGIT DST. There were three samples that showed mutation in PSQ, but the DST RIF was susceptible as these mutation come under the disputed mutation category, wherein the MGIT DST at the critical concentration is sensitive.
DISCUSSION
Currently, the primary tool for the diagnosis of TB is a cartridge-based nucleic acid amplification test. Xpert MTB/RIF test. It features in the diagnostic algorithm in many countries. Studies have shown that Xpert has good sensitivity and specificity of MTB and RIF resistance and is reported to be a game changer for the detection of TB. [2] Our data have shown that there is a possibility that false RIF resistant results on 10/40 samples. All these samples showed a delayed Ct for MTB positive and positive analyte for all the probes present. Contrary to this, when there is a complete dropout of any probe, the result is correlated with PSQ and MGIT RIF DST. This was observed among 27/40 samples. This is in concordance with previous studies in the literature. [6, 7] Single sample with delayed Ct for all probes showed a mutation in PSQ and subsequent resistance to RIF in MGIT DST. WHO has recommended the use of Xpert MTB RIF for the testing of extrapulmonary samples, [8] HIV-positive cases, and pediatric cases. These samples are very often paucibacillary, and Xpert may diagnose with a delayed Ct and resistance to RIF. In cases, especially if RIF resistance is not suspected but resistance is detected, and there is a Ct difference, we suggest the use of another genotypic test followed by MGIT RIF DST be performed before the initiation of multidrug-resistant treatment.
CONCLUSION
The advent of Xpert Ultra with targets IS6110 and IS1081 for MTB may resolve this issue as it does not flag very low but gives the result as MTB-detected trace. [5] RIF resistance detection has also been improved in ultra by relying on the interpretation of the melting curves in the active site of rpoB. [9] Financial support and sponsorship Nil.
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